
## Jason Law

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/176356/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2012, 18, 1656-1663.	2.0	51
2	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow	2.0	16
3	Transplantation, 2019, 25, e145-e154. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 648-661.	2.4	14
4	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	3.5	13
5	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. Transplantation and Cellular Therapy, 2022, , .	1.2	4
6	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
7	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). Blood, 2020, 136, 42-43.	1.4	Ο